CAS 95635-55-5|CAS 142387-99-3|Ranolazine|Ranexa|N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide|@ranolazine|(-)-Ranolazine|ranolazine|Ranolazine Dihydroch...

General Information

Structure

Molecular Formula

C₂₄H₃₃N₃O₄

Molecular Mass

427.53652

Exact Mass

427.24710655

Charge

InChI

InChI=1S/C24H33N3O4/c1-18-7-6-8-19(2)24(18)25-23(29)16-27-13-11-26(12-14-27)15-20(28)17-31-22-10-5-4-9-21(22)30-3/h4-10,20,28H,11-17H2,1-3H3,(H,25,29)

InChIKey

XKLMZUWKNUAPSZ-UHFFFAOYSA-N

Canonic Smiles

COc1ccccc1OCC(CN1CCN(CC1)CC(=O)Nc1c(C)cccc1C)O

Isomeric Smiles

OC(CN1CCN(CC1)CC(=O)Nc1c(cccc1C)C)COc1c(OC)cccc1

Calculated Properties

JChem

LogD (pH = 7.4)

2.74

LogD (pH = 5.5)

1.55

Log P

2.83

Rotatable Bonds

H Donor

H Acceptors

Lipinski's Rule of Five

true

Acid pKa

6.77

Polar Surface Area

74.27

Polarizability

48.36

Molar Refractivity

123.46

LOG S

-3.16

Data Source

Names and Identifiers

IUPAC Traditional name

@ranolazine ranolazine

Synonyms

RanolazineRanexa(-)-RanolazineranolazineRanolazine DihydrochlorideRanolazine 2HClN-(2,6-Dimethylphenyl)-2-(4-(2-hydroxy-3-(2-methoxy-phenoxy)propyl)piperazin-1-yl)acetamideN-(2,6-Dimethylphenyl)-2-(4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)piperazin-1-yl)acetamideN-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide(+/-))-RanolazineRS 43285-003RenexaN-(2,6-Dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazineacetamideCVT 303

IUPAC name

N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide

Brand Name

Ranexa

API Name

Ranolazine

Names and Identifiers

Registration numbers

CAS Number

95635-55-5142387-99-3

MDL Number

MFCD00864690

PubChem CID

56959

PubChem SID

46505145160963591252238170

DrugBank ID

DB00243

ACToR Database

142387-99-395635-55-5

CHEMBL

BKMS React Database

CHEBI ID

LINCS Database

CompTox Database

BRENDA Ligand Database

143790

BRENDA Database

2.3.1.16

SureChEMBL Database

SCHEMBL124665

Registration numbers

Properties

Related Proteins

No Data Available

Click here to submit data

Molecular Spectra

No Data Available

Click here to submit data

Molecule Details

DrugBank

DB00243

Drug Groups

approved; investigational

Description

Ranolazine is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]

Indication

For the treatment of chronic angina. It should be used in combination with amlodipine, beta-blockers or nitrates.

Pharmacology

Ranolazine has antianginal and anti-ischemic effects that do not depend upon reductions in heart rate or blood pressure. It is the first new anti-anginal developed in over 20 years.

Toxicity

In the event of overdose, the expected symptoms would be dizziness, nausea/vomiting, diplopia, paresthesia, and confusion. Syncope with prolonged loss of consciousness may develop.

Affected Organisms

Humans and other mammals

Biotransformation

Hepatic, metabolized mainly by CYP3A and to a lesser extent by CYP2D6. The pharmacologic activity of the metabolites has not been well characterized.

Absorption

Absorption is highly variable. After oral administration of ranolazine as a solution, 73% of the dose is systemically available as ranolazine or metabolites. The bioavailability of oral ranolazine relative to that from a solution is 76%.

Half Life

7 hours

Protein Binding

62%

Elimination

Ranolazine is metabolized rapidly and extensively in the liver and intestine; less than 5% is excreted unchanged in urine and feces.

References

• Hale SL, Kloner RA: Ranolazine, an inhibitor of the late sodium channel current, reduces postischemic myocardial dysfunction in the rabbit. J Cardiovasc Pharmacol Ther. 2006 Dec;11(4):249-55. [Pubmed]

• Fraser H, Belardinelli L, Wang L, Light PE, McVeigh JJ, Clanachan AS: Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts. J Mol Cell Cardiol. 2006 Dec;41(6):1031-8. Epub 2006 Oct 5. [Pubmed]

• Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L: Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006 Aug 1;48(3):566-75. Epub 2006 Jun 15. [Pubmed]

• Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, Wang W, Skettino SL, Wolff AA: Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004 Jan 21;291(3):309-16. [Pubmed]

• Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky S, Wolff AA, Skene A, McCabe CH, Braunwald E: Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2007 Apr 25;297(16):1775-83. [Pubmed]

External Links

• [Wikipedia]

• [RxList]

• [Drugs.com]

Selleck Chemicals

S1799

Research Area: Cardiovascular Disease
Biological Activity:
Ranolazine(Ranexa) is an antianginal medication. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia in rabbits. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia in rats. [1]

TRC

R122500

Ranolazine is an anti-ischemic agent which modulates myocardial metabolism. Antianginal.

ChEBI

CHEBI:87690

An aromatic amide obtained by formal condensation of the carboxy group of 2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetic acid with the amino group of 2,6-dimethylaniline.

Molecule Details

References

PubChem Literature

From Data Sources

• McCormack, J.G., et al.: Gen. Pharmacol., 30, 639 (2004)

• Schofield, J.A.H., et al.: Expert Opin. Invest. Drugs, 11, 117 (2004)

• Chaitman, B.R., et al.: J. Am. Coll. Cardial., 43, 1375 (2004)

References

Bioactivity

PubChem BioAssay

Bioactivity

Names and Identifiers

IUPAC Traditional name

@ranolazine ranolazine

Synonyms

IUPAC name

N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide

Brand Name

Ranexa

API Name

Ranolazine

Registration numbers

CAS Number

95635-55-5142387-99-3

MDL Number

MFCD00864690

PubChem CID

56959

PubChem SID

46505145160963591252238170

DrugBank ID

DB00243

ACToR Database

142387-99-395635-55-5

CHEMBL

BKMS React Database

CHEBI ID

LINCS Database

CompTox Database

BRENDA Ligand Database

143790

BRENDA Database

2.3.1.16

SureChEMBL Database

SCHEMBL124665

Properties

Molecule Details

DrugBank

DB00243

Drug Groups

approved; investigational

Description

Ranolazine is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]

Indication

For the treatment of chronic angina. It should be used in combination with amlodipine, beta-blockers or nitrates.

Pharmacology

Ranolazine has antianginal and anti-ischemic effects that do not depend upon reductions in heart rate or blood pressure. It is the first new anti-anginal developed in over 20 years.

Toxicity

In the event of overdose, the expected symptoms would be dizziness, nausea/vomiting, diplopia, paresthesia, and confusion. Syncope with prolonged loss of consciousness may develop.

Affected Organisms

Humans and other mammals

Biotransformation

Hepatic, metabolized mainly by CYP3A and to a lesser extent by CYP2D6. The pharmacologic activity of the metabolites has not been well characterized.

Absorption

Half Life

7 hours

Protein Binding

62%

Elimination

Ranolazine is metabolized rapidly and extensively in the liver and intestine; less than 5% is excreted unchanged in urine and feces.

References

External Links

• [Wikipedia]

• [RxList]

• [Drugs.com]

Selleck Chemicals

S1799

TRC

R122500

Ranolazine is an anti-ischemic agent which modulates myocardial metabolism. Antianginal.

ChEBI

CHEBI:87690

An aromatic amide obtained by formal condensation of the carboxy group of 2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetic acid with the amino group of 2,6-dimethylaniline.

References

PubChem Literature

From Data Sources

• McCormack, J.G., et al.: Gen. Pharmacol., 30, 639 (2004)

• Schofield, J.A.H., et al.: Expert Opin. Invest. Drugs, 11, 117 (2004)

• Chaitman, B.R., et al.: J. Am. Coll. Cardial., 43, 1375 (2004)

Bioactivity

PubChem BioAssay

Molecule

ID:128